The FDA has approved F1CDx, a comprehensive companion diagnostic test that can detect genetic alterations and two genomic signatures in any type of solid tumor. Patients with five common types of advanced cancer can be matched to one of 17 targeted therapies with this single test.

中文翻译：

---

首次全面诊断伴侣

FDA已批准F1CDx，这是一种全面的伴随诊断测试，可以检测任何类型的实体瘤中的遗传改变和两个基因组特征。可以通过此单一测试将患有五种常见类型的晚期癌症的患者与17种靶向疗法之一进行匹配。